[redactions made under s47F of the FOI Act]
From:
Clinical Guidelines
Sent:
Monday, 16 November 2020 11:45 AM
To:
Subject:
RE: ADHD Guidelines [SEC=OFFICIAL]
Attachments:
progress_report_template_140911 (1).pdf
Dear
Hope you are well and all is progressing nicely with your guideline.
Just a quick note to check in about your progress report for NHMRC that is due shortly. This is based on
a public consultation date of late February 2021.
If anything has changed please don’t hesitate to let us know and I can update the progress report due
date also.
Many thanks & Kind regards,
Sally
Sally Wright
Senior Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
Hours: Mon,Tue & Thur
nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders past and
present.
From: Clinical Guidelines
Sent: Monday, 21 September 2020 4:25 PM
To: Subject: RE: ADHD Guidelines [SEC=OFFICIAL]
Dear
As mentioned last month, please find attached NHMRC’s Progress Report questions which are due 3-6
months prior to your public consultation date, the latest submission date being late November 2020.
1
This report helps us to see how you’re tracking and better understand your guideline development
process.
Could you please complete the questions and email them to xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx.
Many thanks & Kind regards,
Sally
Sally Wright
Senior Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
Hours: Mon,Tue & Thur
nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders past and
present.
From: Clinical Guidelines
Sent: Tuesday, 11 August 2020 8:23 AM
To:
Subject: RE: ADHD Guidelines [SEC=OFFICIAL]
That’s great
. I’ll email again in the next couple of months with NHMRC’s progress report questions.
Kind regards,
Sally
Sally Wright
Senior Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
2
Hours: Tue - Fri
nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders past and
present.
From:
Sent: Tuesday, 4 August 2020 12:30 PM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>; Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>; Admin
<xxxxx@xxxxx.xxx.xx>
Subject: Re: ADHD Guidelines [SEC=OFFICIAL]
Dear Sally,
Thank you for touching base. We are working towards the same deadline with public consultation planned
for Feb 21. I am in evidence synthesis stage now.
Hope you and your family are well too.
Best wishes,
3
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders past and present.
From: Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>
Sent: Thursday, 9 April 2020 8:06 AM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>; Admin <xxxxx@xxxxx.xxx.xx>
Cc:
Subject: Re: ADHD Guidelines [SEC=OFFICIAL]
Dear Sally, many thanks for providing this advice,
We are experiencing some delays associated with COVID-19 but are still tracking ok I think.
We will certainly provide updates on timelines etc
Sincerely
Mark Bellgrove
On Wed, 8 Apr 2020 at 21:36, Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
wrote:
Dear
Just a quick note to provide you with some general information about the approval process.
Most of this information you’re probably familiar with but I thought I might go over it in case
anything is new since the last time you submitted a guideline for approval. I will also touch
base closer to the time that the requirements are due.
To be approved a guideline must meet the
NHMRC guideline standard and follow the
Procedures and requirements for meeting the NHMRC standard for guidelines.
NHMRC Council Meetings
Although there are changes to other NHMRC Committees due to the COVID-19 pandemic, we
understand the Council meetings will still go ahead as planned. The planned dates for 2021 are
11 March and 17 June. The third date for 2021 is to be advised and is most likely to be held in
October or November.
5
Council will be asked to consider the guideline recommendations only and the public
consultation report. All other material (the full guidelines, the technical and administrative
reports etc) will still need to be submitted to NHMRC and may be examined by Council if it
requests it. We will ask that someone from the guideline development group be available, in
person or by video, to answer any questions Council members may have. If Council are happy
then formal confirmation of CEO approval of your guidelines will be sent no more than three
weeks after the meeting.
Progress report
I have attached the progress report template for you to complete and return to NHMRC – this
is should be done 3-6 months before public consultation begins.
Public consultation
I have attached the NHMRC advice on public consultation for you. The main thing to stress is
the importance of sending the draft guidelines to all CEOs, Secretaries or Directors General of
state and territory health departments, explicitly inviting them to make a response. This step
mitigates the risk of the states and territories voicing concerns later on when it is too late to
change the guidelines, and also helps reassure members of council representing states and
territories. We also advise individual NHMRC council members about public consultation and
invite them to make a submission in their individual capacities.
Expert Peer Review Names
I would appreciate you providing me with the names of six people whom we can approach to
provide expert peer review of the draft guidelines, so that we can contact them well ahead of
time. They should be experts in part or all of the guidelines’ subject matter, not involved in
their development and preferably a mix of both international and Australian experts. NHMRC
will also independently source a similar number of experts (noting that the response rate for
timely expert review is usually poor, so the more people who are approached the greater the
possibility of getting reviews back in the required time).
Methodological Review
Please find attached a methodological review template for you to complete and submit to
NHMRC together with the draft guideline. You will see the template asks you to identify
whereabouts in the guideline various pieces of information can be found.
As ever we would appreciate a heads up if the guidelines are likely to be controversial or if
Commonwealth ministers are likely to be lobbied because of anything in them.
Happy to discuss anything here if you need more information. Have a great Easter break and
stay well.
6
Kind regards,
Sally
Sally Wright
Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
Hours: Tue ‐ Fri
nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders past and present.
From:
Sent: Wednesday, 12 February 2020 3:43 PM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
Subject: Re: ADHD Guidelines [SEC=OFFICIAL]
7
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders
past and present.
From:
Sent: Thursday, 23 January 2020 11:06 AM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
Subject: Re: ADHD Guidelines [SEC=OFFICIAL]
Hi Sally,
My apologies for such a delayed response. I hope you had a lovely festive
season.
In response to your points:
Yes, please do email me and perhaps also cc xxxx.xxxxxxxxx@xxxxxx.xxx.
Thank you I can do this.
Is that component of the guidelines for guidelines now available or was it
the public consultation that I saw? If not publicly available, I would love to
keep a copy.
9
CC in other members of the guideline development
group?
* The conflict of interest and Aboriginal
and Torres Strait Islander 'Guidelines for
Guidelines' modules were noted in the discussion
minutes. Is this something we mentioned in passing
or would you like a copy of the module if it is
available?
* Just confirming the date February 2021 is
for public consultation of the draft guideline and
June 2021 is submission of the draft guideline to
NHMRC Council? Are you considering 30 or 60 days
for your public consultation? It's ok if these
dates are not locked in. I will touch base again
regarding any date changes and the progress report
a few months prior to PC.
* A public consultation process was noted
for the questions in scope. Is this something
you're planning for next year?
Thanks very much
and apologies for missing
the first meeting. If you have any questions
please don't hesitate to contact me via the
clinical guidelines mailbox
xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx<mailto:clinicalgui
xxxxxxx@xxxxx.xxx.xx> or directly on 03 8866 0411.
Kind regards,
Sally
Sally Wright
Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
nhmrc.gov.au
[Logo-inline-tagline-purple]
I acknowledge the Traditional Custodians of the
lands around Australia and pay my respects to
Elders past and present.
[cid:image001.gif@01D46089.791BAD30]
This email (including any attached files) is
intended only for the addressee, it may contain
confidential information. If you are not the
addressee, you are notified that any transmission,
distribution, printing or duplication of this
email is strictly prohibited. If you have received
this email in error please promptly inform the
sender and delete all copies of this e-mail and
all attachments.
Unless explicitly attributed, the opinions
expressed do not necessarily represent the
11
official position of the National Health and
Medical Research Council.
Please consider the environment before printing
this email, thank you.
This email (including any attached files) is intended only for
the addressee, it may contain confidential information. If you
are not the addressee, you are notified that any transmission,
distribution, printing or duplication of this email is
strictly prohibited. If you have received this email in error
please promptly inform the sender and delete all copies of
this e-mail and all attachments.
Unless explicitly attributed, the opinions expressed do not
necessarily represent the official position of the National
Health and Medical Research Council.
Please consider the environment before printing this email,
thank you.
This email (including any attached files) is intended only for the
addressee, it may contain confidential information. If you are not the
addressee, you are notified that any transmission, distribution, printing
or duplication of this email is strictly prohibited. If you have received
this email in error please promptly inform the sender and delete all
copies of this e-mail and all attachments.
Unless explicitly attributed, the opinions expressed do not necessarily
represent the official position of the National Health and Medical
Research Council.
Please consider the environment before printing this email, thank you.
--
PROFESSOR MARK A. BELLGROVE
Director of Research, Turner Institute for Brain and Mental Health
National Health and Medical Research Council (NHMRC) Senior Research Fellow
President, Australian ADHD Professionals Association (AADPA) Ltd
Turner Institute for Brain and Mental Health
School of Psychological Sciences
Monash University
Room 540, 18 Innovation Walk
Clayton Campus, Clayton VIC 3800
Australia
T:
E: xxxx.xxxxxxxxx@xxxxxx.xxx
ORCID: orcid.org/0000-0003-0186-8349
http://www.monash.edu.au/research/profiles/profile.html?sid=1985044&pid=6456
http://www.monash.edu/turner-institute/
I acknowledge the Traditional Owners and Custodians of the lands on which I live and work and pay my respect to
Elders both past and present
This email (including any attached files) is intended only for the
addressee, it may contain confidential information. If you are not the
addressee, you are notified that any transmission, distribution, printing
or duplication of this email is strictly prohibited. If you have received
this email in error please promptly inform the sender and delete all
copies of this e-mail and all attachments.
12
Unless explicitly attributed, the opinions expressed do not necessarily
represent the official position of the National Health and Medical
Research Council.
Please consider the environment before printing this email, thank you.
13
VERSION: 2 | EFFECTIVE DATE: 10/02/14
PROGRESS REPORT TEMPLATE
To confirm the intention to seek the National Health and
5. Describe the processes to be used for declaration and
Medical Research Council (NHMRC) approval for a clinical
management of competing interests for all people involved in
practice guideline, the developer must submit a progress report
the guideline development process.
approximately 6 months (and not later than 3 months) before
6. Describe the processes that will be/are being used to ensure
the draft guideline is released for public consultation. NHMRC
consumer perspectives are incorporated in the guideline.
will inform the developer in writing if any major issues or gaps in
the development process are identified within 4- 8 weeks from
7. List the organisations (if any) that will be approached to
receipt of the progress report.
endorse the guideline.
Scope and purpose
The progress report should be submitted
electronically to NHMRC at:
8. List the clinical research questions which are being
xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx
addressed by the guideline that inform the evidence review.
9. List the population groups to which the guideline
Please ensure the full guideline title is included
recommendations will apply and any population subgroups
at the start of the progress report. The progress
for whom specific information may be required (such as risks
report should not exceed 15 pages in length.
or treatment considerations).
10. List any issues (such as particular risks, treatment
If delays occur in the guideline development which alter the
considerations or sociocultural considerations) identified as
timeframes for the public consultation and/or final submission
relevant to Aboriginal and Torres Strait Islander peoples or any
dates, further progress reports may be requested by NHMRC.
other groups (eg culturally and linguistically diverse (CALD)
groups) which will be considered as part of the guideline
Governance and stakeholders
scope, and describe how these issues have been addressed
in the evidence review and formulation of recommendations.
1. List the key organisation or organisations responsible for
development and publication of the guideline.
Evidence review
2. List the sources of all funding for the development of the
11. List the names of the evidence experts who will be involved in
guideline and its publication.
the search and appraisal of the literature (if not provided at 4).
3. Describe the processes for ensuring editorial independence
12. List the publication date cut points (as month/year) for
from funders.
all evidence searches, including any differences if multiple
4. List all the people involved in the guideline development
searches were completed as part of the evidence
process (including discipline/expertise, organisational
review process.
affiliation and role in the guideline development process).
| PAGE 1 of 2
Recommendations
Dissemination and implementation
13. List the types of recommendations which have been or
18. List the organisations/agencies who will be responsible
will be derived from the clinical questions. For example,
for the implementation of the final guideline.
these may include recommendations based on a systematic
19. Provide a summary of the dissemination plan for the
evidence review, recommendations developed where a
final guideline.
systematic evidence review was conducted and low quality
or no evidence was identified (and consensus processes may
20. List the tools and resources that will be developed to
have been used) and recommendations developed to provide
accompany the guidelines.
additional information to support recommendations where a
Key dates
systematic evidence review was not conducted (sometimes
called practice points or points of note).
21. Provide the start and end dates for the public consultation
14. Describe the process which will be used to reach expert or
period.
group consensus in the development of recommendations.
22. Provide the intended submission date of the final draft
guideline for NHMRC approval.
Consultation
General
15. Indicate whether any recommendations will specify the use
of medicines or services that are currently not available or
23. Summarise any difficulties or delays which have been
restricted in Australia, and how the relevant authority/ies will
encountered in progressing the development of the
be consulted.
guideline to date.
16. List any organisations/individuals that will be specifically
24. Provide details of any controversial or contentious issues
approached to provide comment on the guideline.
associated with the guideline content or development process.
17. Describe the processes that are in place to collaborate with
organisations that are producing/have produced advice
in related areas. For example they may be involved in the
review of evidence, review of drafts, and/ or notified when
potentially conflicting recommendations are proposed.
VERSION: 2 | EFFECTIVE DATE: 10/02/14 | PAGE 2 of 2
